News

ViiV Healthcare unveiled new data at the Conference on Retroviruses and Opportunistic Infections on next-generation long-acting HIV therapies.

Blocking the protein P2RX7 in regulatory T cells boosted antibody responses, and this discovery could one day lead to strategies for enhancing existing immunotherapies in non-small lung cancer.

Risant’s CEO, Jaewon Ryu, M.D., J.D., discusses some of the early successes of bringing a set of Kaiser Permanente’s value-based care practices to Risant's health systems—Geisinger Health in Pennsylvania and Cone Health in North Carolina. Consistency and "systemness” are key.

The president slammed the Affordable Care Act and talked up his Great Health Plan and his most favored nation drug pricing policies, highlighting lower prices for fertility drugs.

Cardinal Health 2026 Biosimilars Report shows biosimilars’ savings surge, but predictable reimbursement drives physician adoption amid FDA streamlining.

Catastrophic cases are often a strategic vulnerability for health plans with outsized influence on cost, outcomes and member experience.

An abstract presented at CROI 2026 found that continuous Medicaid coverage during the COVID-19 public health emergency was associated with decreased dependence on AIDS Drug Assistance Programs.

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

The role of the pharmacist, managed care pharmacist job satisfaction and artificial intelligence were among the topics that Susan A. Cantrell, CEO of the Academy of Managed Care Pharmacy, discussed with Perry Cohen, Pharm.D., in this episode of "Conversations with Perry and Friends."

The deals that drugmakers have struck in response to Trump's most favored nation pricing policies may not be affected, partly because the president has authority to impose tariffs under other statutes.

Early pharmacy leadership helps health systems build safe, sustainable cell and gene therapy programs, aligning contracts, workflows, regulations and payer realities.

Health systems learn why cell and gene therapy success depends on workflows, staffing, and finances—not just science—and how to build them.

Zimbabwe has become one of the first countries in the world to launch a national lenacapavir program, introducing the twice-yearly injectable HIV prevention drug as part of its ongoing efforts to reduce new infections and end AIDS as a public health threat.

In this video interview, Joseph Kleiman, president of Buzz Health, says that patients should always “do their homework” to see if they are paying the lowest possible price for their prescription, whether that’s through TrumpRx or another website.

Researchers say a modest price cut would make semaglutide cost-effective for secondary prevention of cardiovascular disease in the United States.

In this Q&A, Jessica Vazzaz explained what evidence supports sonic sleep aids, who benefits and what payers should demand before covering sleep-disorder apps.

The National Specialty Care Access Coalition aims to standardize care models, modernize reimbursement policies, and pilot programs in cardiology, neurology, and maternal-fetal medicine nationwide.

FDA reviews tirabrutinib for relapsed/refractory primary CNS lymphoma under accelerated approval, with promising phase 2 response rates and a Dec. 2026 decision.

Leaders of the smaller PBMs say they’ve always been transparent, pass-through companies, and complying with the new law’s reporting requirements is not a heavy lift.

A conversation with Joseph Kleiman emphasizes price transparency, consumer research and the need for consistent pricing and drug availability.

A study of older women suggests that greater muscle strength lowers the risk of death, regardless of other factors like sedentary behavior.

A number of recent studies suggests that shingles vaccine has benefits beyond just protecting against shingles.

A multicenter Swedish study finds influenza vaccination during immunotherapy is associated with longer survival, particularly in people being treated for melanoma, without increasing immune-related side effects.

Jessica Vazzaz, a doctoral researcher and tutor in psychology at the University of Sussex, shared that health plans should require large, well-designed randomized trials before covering sonic sleep aids. She added that benefits are likely fair and could vary by individual, making it critical to understand who these tools actually help and under what conditions.

Citing updated scientific evidence, the FDA has revised safety labels for six menopause hormone therapies, removing previous boxed warnings to better reflect current understanding of their risks and benefits for women in early menopause